Susan Evans‐Axelsson
Lund University(SE)Bayer (Germany)(DE)
Publications by Year
Research Areas
Prostate Cancer Treatment and Research, Radiopharmaceutical Chemistry and Applications, Prostate Cancer Diagnosis and Treatment, Statistical Methods in Clinical Trials, Radiomics and Machine Learning in Medical Imaging
Most-Cited Works
- → Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer(2018)87 cited
- → Treatment with the WNT5A-mimicking peptide Foxy-5 effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse model(2017)73 cited
- → Mechanisms of Resistance to Prostate-Specific Membrane Antigen–Targeted Radioligand Therapy in a Mouse Model of Prostate Cancer(2020)52 cited
- → Establishing 177Lu-PSMA-617 Radioligand Therapy in a Syngeneic Model of Murine Prostate Cancer(2017)51 cited
- → The STAT3 Inhibitor Galiellalactone Effectively Reduces Tumor Growth and Metastatic Spread in an Orthotopic Xenograft Mouse Model of Prostate Cancer(2015)49 cited
- → Introducing PIONEER: a project to harness big data in prostate cancer research(2020)39 cited
- → Microscale radiosynthesis, preclinical imaging and dosimetry study of [18F]AMBF3-TATE: A potential PET tracer for clinical imaging of somatostatin receptors(2018)36 cited
- → Preclinical Characterization of 3β-(N-Acetyl l-cysteine methyl ester)-2aβ,3-dihydrogaliellalactone (GPA512), a Prodrug of a Direct STAT3 Inhibitor for the Treatment of Prostate Cancer(2016)35 cited
- → Inhibition of STAT3 augments antitumor efficacy of anti-CTLA-4 treatment against prostate cancer(2021)33 cited
- → Molecular Pathways in the Progression of Hormone-Independent and Metastatic Prostate Cancer(2010)33 cited